Skip to main content

Table 2 Physical and 2DE structural and functional parameters at baseline

From: The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

  Level Parameter Group
Control Empagliflozin
   Body weight [gr] 413 ± 35 395 ± 37
Apical level Systolic LVESA [mm2] 16.4 ± 5.9 15.8 ± 5.3
LVIDs [mm] 4.2 ± 0.7 4.6 ± 0.7
Diastolic LVEDA [mm2] 43.3 ± 4.9 39.2 ± 5.4
LVIDd [mm] 7.6 ± 0.6 7.0 ± 0.6
Function FS [%] 39.7 ± 3.9 35.6 ± 3.8
FAC [%] 63.1 ± 3.7 59.0 ± 3.7
EF [%] 74.5 ± 6.4 70.4 ± 6.2
Papillary muscles level Systolic LVESA [mm2] 20.5 ± 4.3 26.2 ± 4.3
LVIDs [mm] 4.3 ± 0.6 4.9 ± 0.7
Diastolic LVEDA [mm2] 51.2 ± 4.7 47.1 ± 4.6
LVIDd [mm] 7.5 ± 0.6 7.3 ± 0.5
Function FS [%] 36.2 ± 3.1 39.7 ± 3.2
FAC [%] 52.3 ± 3.6 56.2 ± 4.0
EF [%] 69.9 ± 5.3 76.4 ± 5.4
  1. LVESA, LVEDA—LV end systolic and end diastolic area, respectively. LVIDs, LVIDd—LV end systolic and end diastolic internal diameter, respectively. FS fractional shortening, FAC fractional area change, EF ejection fraction